Table 3. Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).
| Overall | HCV genotype N. of failures/N. of treated patients (%) |
||||||
|---|---|---|---|---|---|---|---|
| DAA regimen | N. of failures/N. of treated patients (%) | 1a | 1b | 2 | 3 | 4 | 5 |
| 139/3830 (3.6) | |||||||
| SOF+RBV |
68/710 (9.6) |
5/15 (33.3) |
20/56 (35.7) |
8/499 (1.6) |
32/132 (24.2) |
3/8 (37.5) |
- |
| SOF+SIM±RBV |
38/683 (5.6) |
8/99 (8) |
24/520 (4.6) |
1/2 (50) |
1/1 (100) |
3/60 (5) |
1/1 (100) |
| SOF+LDV±RBV |
16/1002 (1.6) |
3/200 (1.5) |
10/752 (1.3) |
- |
0/1 (0) |
3/44 (6.8) |
0/5 (0) |
| 3D±RBV |
9/894 (1) |
3/86 (3.5) |
6/806 (0.7) |
- |
- | 0/2 0 |
- |
|
2D+RBV |
2/64 (3.1) |
- | - | - | - | 2/59 3.4% |
0/5 (0) |
| SOF+DCV±RBV |
6/471 (1.3) |
0/47 0 |
1/115 (0.9) |
0/55 (0) |
5/244 (2) |
0/10 (0) |
|
| SIM+DCV |
0/6 (0) |
- | 0/6 (0) |
- | - | - | - |